GlassScriptPhysician profile
Eric Alan Harvester
NPI 1689153579
$3,683.78
in general payments reported to CMS, 2019-2025
20 companies · $2,139 in 2025
The $2,139 reported for 2025 was more than what 97% of Critical Care Medicine (Nurse Practitioner) providers received nationally (typical 2025 total: $118).
See the full distribution for Critical Care Medicine (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $223 · 2023: $123 · 2024: $1,080 · 2025: $2,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,342.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $696.61 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $317.70 | 2022-2025 | Breyanzi, Camzyos |
| Madrigal Pharmaceuticals | $285.48 | 2025 | Rezdiffra |
| Neurocrine Biosciences, INC. | $260.57 | 2024-2025 | Ingrezza |
| Sage Therapeutics, LLC | $219.52 | 2024-2025 | |
| Abiomed | $217.10 | 2024-2025 | Impella |
| Abbvie INC. | $212.65 | 2025 | |
| Haemonetics Corporation | $148.43 | 2024-2025 | Teg6s Hemostasis System |
| Medtronic, INC. | $147.24 | 2025 | Symplicity G3 |
| Abbott Laboratories | $142.17 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Genzyme Corporation | $134.19 | 2025 | |
| Jazz Pharmaceuticals INC. | $130.84 | 2024 | |
| Stryker Corporation | $124.99 | 2025 | Mild Device Kit |
| Ipsen Biopharmaceuticals, INC | $120.79 | 2025 | Iqirvo |
| Axsome Therapeutics, INC. | $120.53 | 2025 | Symbravo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $120.34 | 2025 | Arexvy |
| United Therapeutics Corporation | $94.88 | 2025 | |
| Gilead Sciences, INC. | $92.99 | 2024 | Vemlidy |
| Inspire Medical Systems, INC. | $84.34 | 2024 | Inspire |
| Atricure, INC. | $12.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Harvester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.